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the expense of caring for men with early stage prostate
cancer. OBJECTIVE: To compare the cost and resource
utilization in the work up, treatment and 6 month follow
up of African American and white men undergoing either
external beam radiation therapy (XRT) or radical pros-
tatectomy for early stage prostate cancer. DESIGN: Ret-
rospective analysis of cost and resource utilization data
from encrypted patient-specific hospital inpatient, hospi-
tal outpatient, and physician/supplier data files. PAR-
TICIPANTS: A random 5% national sample of Medicare
beneficiaries (n  8750) from the Health Care Financing
Administration (HCFA) Public Use Files for calendar
years 1993 through 1996. MAIN OUTCOME MEA-
SURES: Inpatient, outpatient and physician/supplier-
Medicare costs. RESULTS: African American men un-
dergoing radical prostatectomy for early stage prostate
cancer had significantly higher costs ($21,878 vs $18,786,
P  0.0001) than did white men. Most of the difference
occurred in the inpatient setting. African American men
undergoing external beam radiation therapy (XRT) had
significantly greater costs ($18,131 vs $15,734, P 
0.0001) than did white men. Most of this difference was
generated by longer duration of XRT treatments. CON-
CLUSIONS: In early stage prostate cancer, costs of treat-
ment with either radical prostatectomy or XRT in Afri-
can American men are higher than in white men.
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Colonoscopy procedure is effective in colorectal cancer
surveillance. An understanding of variations in the cost
or charge for this procedure would aid in designing eco-
nomic evaluations of colorectal cancer screening and pre-
vention strategies. OBJECTIVE: To examine charges re-
lated to colonoscopy and differences therein based on
type of colonoscopy and malignancy status. METHODS:
Data were from the PharMetrics Outcomes Database, an
aggregated administrative database of 35 managed care
plans. Colonoscopy procedures (N  4,055) between
January 1 to June 30, 1997 were identified. The CPT
codes were used to identify the type of colonoscopy (with
or without polypectomy) and the ICD-9 codes were used
to determine diagnostic outcomes (malignant, benign, or
no tumor) of colonoscopy. Charges associated with the
visit and colonoscopy procedure were identified and dif-
ferences determined using the ANOVA or t-test ap-
proach. RESULTS: Fifty-five percent of patients were fe-
males and 77% were greater than 50 years old. A majority
(83%) of benign neoplasm patients had colonoscopy
with polypectomy vs. 57% for malignant neoplasm pa-
tients. The overall mean charges for a colonoscopy visit
was $2536, of which colonoscopy procedure charge was
$1146. The mean charges for colonoscopy procedure ac-
companied by polypectomy was $1245 and colonoscopy
without polypectomy was $971 (P  0.05). A similar
trend was observed with the total colonoscopy visit
charges. Statistically significant differences (P  0.05) in
mean colonoscopy procedure charges between benign
($1208) versus no neoplasm ($1000), benign versus ma-
lignant ($1100), and malignant versus no neoplasm
groups were observed. CONCLUSION: Differences in
colonoscopy-related charges based on type and malig-
nancy status need to be accounted for in the economic
evaluation of colorectal cancer screening and prevention
strategies.
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PURPOSE: Many factors contribute to anemia in cancer
patients. Conventionally, red blood cell transfusions are
used to treat anemia; however, recombinant human ery-
thropoietin (rhEPO) may provide an alternative. Erythro-
poietin is a hematopoietic growth factor normally secreted
by the kidneys to stimulate red blood cell production. Be-
cause of both cost and the lack of response in some can-
cer patients, this study attempted to identify potential in-
dicators for screening patients prior to the use of rhEPO.
METHODS: A retrospective review of oncology patient
records was conducted to examine response rate, evalu-
ate predictors of response, and conduct a pharmacoeco-
nomic analysis comparing use of rhEPO versus transfu-
sion. The review included 310 patients who received
rhEPO within an eighteen-month period from approxi-
mately January 1997 to June 1998. The ADAMS data-
base and pharmacy records were used to collect data that
included serum erythropoietin prior to therapy, duration
and dose of rhEPO, hemoglobin levels, and transfusions
received. Patients were classified into five categories ac-
cording to their response to therapy: success, late response,
partial response, failure and inconclusive. RESULTS: Of
the 310 patients reviewed, 193 were evaluable. Successful
responders comprised only 18.1%, with late responders
and partial responders at 5.7% and 1.6%, respectively.
74.6% of the patients failed to respond to rhEPO treat-
ment. Cost of rhEPO therapy and transfusions was deter-
mined for each patient. CONCLUSIONS: This study de-
termined that in the majority of cases, the use of rhEPO
to treat anemia in cancer patients is cost prohibitive com-
pared to transfusion. Examining predictive indicators of
response for rhEPO can save time and money for the pa-
tient as well as the treating facility. Prescreening for pre-
dictive indicators in anemic cancer patients would im-
prove the likelihood of successful treatment.
